Physician profile
Nicole Ryan
NPI 1972668234
$786.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $42.87 · 2022: $229 · 2023: $175 · 2024: $90.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $214.95 | 2022 | |
| Greenwich Biosciences, INC. | $176.27 | 2019 | |
| Biogen, INC. | $91.50 | 2023 | Tysabri |
| Shire North American Group INC | $46.16 | 2019 | |
| Immedica Pharma US, INC. | $44.57 | 2023 | |
| Pfizer INC. | $33.02 | 2020-2024 | |
| Novo Nordisk INC | $28.68 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $28.08 | 2024 | |
| Sanofi Pasteur INC. | $27.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $25.38 | 2019-2020 | |
| Exact Sciences Corporation | $21.00 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $18.53 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.